Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA.

Am J Cardiol. 2017 Feb 1;119(3):397-403. doi: 10.1016/j.amjcard.2016.10.027.

2.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.

Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Braeckman RA, Stirtan WG, Soni PN, Juliano RA.

Atherosclerosis. 2016 Oct;253:81-87. doi: 10.1016/j.atherosclerosis.2016.08.005.

3.

Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.

Bays HE, Ballantyne CM, Doyle RT Jr, Juliano RA, Philip S.

Prostaglandins Other Lipid Mediat. 2016 Sep;125:57-64. doi: 10.1016/j.prostaglandins.2016.07.007.

4.

A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States.

Philip S, Chowdhury S, Nelson JR, Benjamin Everett P, Hulme-Lowe CK, Schmier JK.

J Med Econ. 2016 Oct;19(10):1003-10. doi: 10.1080/13696998.2016.1207652.

PMID:
27352086
5.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA.

J Clin Lipidol. 2016 May-Jun;10(3):635-645.e1. doi: 10.1016/j.jacl.2016.02.008.

6.

Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.

Reddy KJ, Chowdhury S.

Future Cardiol. 2016 May;12(3):261-8. doi: 10.2217/fca-2015-0009.

7.

Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.

Ferreira JJ, Rosser A, Craufurd D, Squitieri F, Mallard N, Landwehrmeyer B.

Mov Disord. 2015 Sep;30(10):1426-9. doi: 10.1002/mds.26308.

PMID:
26175332
8.
9.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA.

J Clin Lipidol. 2015 May-Jun;9(3):377-83. doi: 10.1016/j.jacl.2014.11.009.

10.

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA.

Metab Syndr Relat Disord. 2015 Aug;13(6):239-47. doi: 10.1089/met.2014.0137.

PMID:
25893544
11.

Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig. 2015 Jan;35(1):45-51. doi: 10.1007/s40261-014-0252-8.

12.

Predictive Modeling to Assess Predictors of Treatment Success and Failure Among Combination Statin Therapy Patients.

Nyandege A, Burudpakdee C, Philip S.

Value Health. 2014 Nov;17(7):A546. doi: 10.1016/j.jval.2014.08.1772. No abstract available.

13.

Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.

Braeckman RA, Stirtan WG, Soni PN.

Drugs R D. 2014 Sep;14(3):159-64. doi: 10.1007/s40268-014-0053-9.

14.

Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig. 2014 Jul;34(7):449-56. doi: 10.1007/s40261-014-0194-1.

PMID:
24760401
15.
16.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN.

Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201. doi: 10.1016/j.plefa.2013.07.005.

PMID:
23992935
17.

Flux duality in nonlinear GMA systems: implications for metabolic engineering.

Marin-Sanguino A, Mendoza ER, Voit EO.

J Biotechnol. 2010 Sep 1;149(3):166-72. doi: 10.1016/j.jbiotec.2009.12.009.

PMID:
20015458
18.

[Radiotherapy in dermatology].

Marín A, Vargas-Díez E, Cerezo L.

Actas Dermosifiliogr. 2009 Apr;100(3):166-81. Review. Spanish.

PMID:
19457302
19.

Metabolic Engineering with power-law and linear-logarithmic systems.

Marin-Sanguino A, Torres NV, Mendoza ER, Oesterhelt D.

Math Biosci. 2009 Mar;218(1):50-8. doi: 10.1016/j.mbs.2008.12.010.

PMID:
19174172
20.

Optimization of biotechnological systems through geometric programming.

Marin-Sanguino A, Voit EO, Gonzalez-Alcon C, Torres NV.

Theor Biol Med Model. 2007 Sep 26;4:38.

Items per page

Supplemental Content

Loading ...
Support Center